Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Investigation of Serum Interleukin-20 Level and Paclitaxel-Associated Neuropathy in Breast Cancer Patients Receiving Paclitaxel Chemotherapy

NCT05622617 is registered in ClinicalTrials.gov with Namik Kemal University as lead sponsor.

NCT NCT05622617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05622617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Investigation of Serum Interleukin-20 Level and Paclitaxel-Associated Neuropathy in Breast Cancer Patients Receiving Paclitaxel Chemotherapy
Lead sponsor
Namik Kemal University
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2022
Completion date
April 1, 2023
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuropathy associated with dysproteinaemias